Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192981 | 1.00 | LTA4H (0.64) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL12463949 | 0.88 | HDAC1 (0.62) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL192410 | 0.86 | HDAC1 (0.54) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL192409 | 0.86 | HDAC1 (0.54) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL191992 | 0.82 | HDAC1 (0.48) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL191993 | 0.82 | HDAC1 (0.48) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL29180030 | 0.78 | HDAC1 (0.68) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL8984803 | 0.76 | LTA4H (0.71) | LTA4H | |
| SCHEMBL12463933 | 0.76 | LTA4H (0.62) | LTA4HHDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL31635263 | 0.76 | HDAC1 (0.83) | LTA4HHDAC1HDAC2HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877366-B1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2012-01-04 | — | — | EP | disclosed |
| EP-1877366-B1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-1877366-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | LTA4H 2416/4885HDAC1 1/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.